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Abstract
 
Gram-positive organisms like 
 
Staphylococcus aureus
 
 are a major cause of morbidity and mortality
worldwide. Humoral response molecules together with phagocytes play a role in host responses
to 
 
S. aureus.
 
 The mannose-binding lectin (MBL, also known as mannose-binding protein) is an
oligomeric serum molecule that recognizes carbohydrates decorating a broad range of infectious
agents including 
 
S. aureus
 
. Circumstantial evidence in vitro and in vivo suggests that MBL plays
a key role in first line host defense. We tested this contention directly in vivo by generating
mice that were devoid of all MBL activity. We found that 100% of MBL-null mice died 48 h
after exposure to an intravenous inoculation of 
 
S. aureus
 
 compared with 45% mortality in wild-
type mice. Furthermore, we demonstrated that neutrophils and MBL are required to limit
intraperitoneal infection with 
 
S. aureus
 
. Our study provides direct evidence that MBL plays a
key role in restricting the complications associated with 
 
S. aureus
 
 infection in mice and raises the
idea that the MBL gene may act as a disease susceptibility gene against staphylococci infections
in humans.
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Introduction
 
A basic function of innate immunity is restriction of the
early proliferation of infectious agents (1, 2). Numerous
molecules and effector cells conspire to restrict this initial
spread of an infectious focus. Some examples of first line
host defense molecules include antimicrobial peptides,
natural antibodies, complement proteins, lipopolysaccharide-
binding protein (LBP), soluble receptors, and collectins
(3–5). The collectins are multimeric carbohydrate recog-
nition domain-containing molecules with collagen stalks
that include the pulmonary surfactant proteins A and D,
conglutinin, CL-43, CL-46, and the mannose-binding
lectin (MBL; 6–9)
MBL appears to be a prototypic pattern recognition mol-
ecule that is able to recognize the molecular patterns that
decorate a wide range of microorganisms. Infectious agents
that are recognized by MBL include certain Gram-positive
and Gram-negative bacteria, yeast, parasites, mycobacteria,
and viruses (7, 10). MBL was first surmised to play a role in
host defense based on its overall structural similarity with
the first complement component C1q (11, 12). Next, in
vitro observations demonstrated that MBL could bind and
opsonize bacteria as well as the yeast cell wall product
mannan (13). The idea that a relative lack of MBL might
predispose the host to infection was based on the description
of an MBL-dependent opsonic defect in human serum that
correlated with a phenotype of recurrent infection (14).
These patients were found to have one of three amino acid
substitution single nucleotide polymorphisms in exon 1 of the
MBL gene that disrupts the collagen helix (15). It appears that
the disordered collagen chain acts like a dominant negative
that results in a decrease in circulating levels of MBL that can
activate complement. More detailed analysis of the MBL
gene has revealed at least seven distinct MBL haplotypes in
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humans, four of which (LYPB, LYQC, HYPD, and LXPA)
dictate low serum levels (16). Interestingly, there is a high rate
of haplotype variation in various human populations with a
range of heterozygosity from 15% in Caucasians to 30% in
certain African populations (17, 18).
Importantly, MBL seems to be able to distinguish species
self as well as altered self, e.g., in the form of apoptotic cells
from nonself (19). The specificity that allows the distinc-
tion of surfaces of virally infected cells and transformed cells
from normal host cells depends on both fine recognition of
molecular patterns and a macropattern (3). The macropat-
tern appears to be dictated by the spatial orientation of the
carbohydrate-binding domains and the differences in ge-
ometry of the sugars that adorn microorganisms versus host
glycoproteins (3, 20, 21). MBL is able to activate comple-
ment via a novel mechanism that coopts the MBL-associ-
ated serine protease (MASP; 22, 23), MASP-2, which then
mimics the classical pathway convertase to cleave the third
complement component (C3; 23). In this way the MBL
complement pathway is activated in an antibody-indepen-
dent manner. Therefore, MBL has many functional prop-
erties that are reminiscent of an antibody and in fact MBL
is considered an opsonin (13,14, 24–26).
The initial response to infection is a complex interaction
between a variety of pattern recognition molecules that
trigger the downstream physiological cascades of clotting,
cytokine, and chemokine release and interface with effec-
tor cells such as neutrophils (27, 28). Neutrophils express
complement receptors, MBL receptors (collectin receptors;
29, 30), and the receptor for LBP (31). Wright and Douglas
(32) and Silverstein (33) linked humoral and cellular inter-
actions and drew attention to the importance of coopera-
tive interactions between neutrophils and opsonins in com-
bating infection. More recent examples that have exploited
the use of null animals to explore such interactions and are
germane to this study include the interaction of LBP and
neutrophils in resistance to i.p. 
 
Salmonella
 
 infection (34,
35). A similar synergistic interaction between neutrophils
and MBL is suggested by clinical observations that chemo-
therapy-induced neutropenic patients with haplotypes that
specify low serum MBL levels (9, 36, 37) appear more sus-
ceptible to infection (38). These clinical observations to-
gether with in vitro studies suggest that MBL plays a key
role as an ante-antibody in first line host defense (39, 40)
and support a role for MBL in combating infection in vivo.
To provide formal proof that MBL is indeed important
in host defense in vivo
 
,
 
 we set out to create a mouse model
of MBL deficiency. Although humans and new world
monkeys have a single MBL gene, two homologous forms
of MBL, designated MBL-A and MBL-C, have been iden-
tified in rodents (41, 42). MBL-A and MBL-C, the respec-
tive gene products of the 
 
mbl1
 
 and 
 
mbl2
 
 genes, are 50%
homologous (43), have distinct and overlapping binding
specificities (43–45), are found predominantly in serum,
and are able to bind MASPs to activate complement (43).
The relative physiological role of these two proteins in vivo
has not been clearly defined (43, 46–49). To address some
of these questions we created MBL-A and MBL-C double
KO (MBL-null) mice. These MBL-null mice lack MBL in
serum and lack the MBL complement pathway. We chose
to infect these mice with 
 
Staphylococcus aureus
 
 as this organ-
ism is a significant cause of bacteremia in humans world-
wide (50, 51). Treatment of 
 
S. aureus
 
 infections is in-
creasingly problematic with the emergence of widespread
antibiotic resistance (52, 53). Although there are clinical
identifiers that indicate likelihood of complication as a re-
sult of 
 
S. aureus
 
 infection, there is a paucity of data that per-
tains to genetic variation in host factors that confer resis-
tance to 
 
S. aureus
 
. We found that MBL-null mice are
highly susceptible to an i.v. inoculation of 
 
S. aureus
 
 as at
48 h after inoculation all MBL-null mice had died com-
pared with 55% survival of WT mice. In contrast, i.p. inocu-
lation of 
 
S. aureus
 
 did not result in enhanced infectious
complications in MBL-null mice compared with WT mice
unless mice were rendered neutropenic but not neutropenic
WT mice. The neutropenic MBL-null mice displayed en-
hanced bacterial accumulation in organs and had persistent
bacteremia 10 d after inoculation. Our results are consistent
with a proposed role for MBL in first line host defense.
 
Materials and Methods
 
Generation of MBL-null Mice.
 
A genomic DNA clone encod-
ing MBL-C was isolated from a 129SvJ library in Lambda Fix II
vector (Stratagene) and mapped (54). The MBL-C gene was dis-
rupted by introducing the neomycin resistance gene (neo
 
r
 
) into
exon 6. The MBL-C gene-targeting construct consists of a 4.5-
kb PmeI-NotI fragment toward the 5
 
  
 
end followed by neo
 
r
 
, and
then a 1.5-kb PacI-SrfI fragment toward the 3
 
  
 
end in a KO3
vector (see Fig. 1 a; provided by K. Moore, Massachusetts Gen-
eral Hospital, Boston, MA). 17 out of 111 embryonic stem cell
clones underwent homologous recombination. This was con-
firmed by Southern blot analysis (not depicted). The positive em-
bryonic stem cell clones were injected into C57Bl/6J blastocysts
at the Transgenic and Knockout Mouse Core Facility at Massa-
chusetts General Hospital, directed by Dr. E. Li. Genotyping was
performed by PCR. A colony of MBL-C KO mice was ex-
panded and some were crossed with MBL-A KO (48) mice to
create MBL-null mice. All animal experiments were performed
under a protocol approved by the Subcommittee on Research
Animal Care at Massachusetts General Hospital.
 
RT-PCR.
 
RT-PCR has been described (48).
 
Detection and Assay of MBLs.
 
The assay for MBL has been
described (46). Complement component 4 (C4) cleaving activity
of purified MBLs and recombinant human MBL (rhMBL) was
measured by previously reported methods (55) with modifica-
tion. In brief, microtiter wells were coated with mannan and a
diluted mixture of different amounts of MBLs in 2.5% MBL-null
mouse serum was added to the wells. After incubation at 37
 
 
 
C
and rinsing, deposited C4 fragments were detected with biotinyl-
ated monoclonal anti–mouse C4 followed by europium-labeled
streptavidin and measurement by time-resolved fluorometry. C4
converting activity in mouse serum was measured for the MBL
complement pathway and the classical pathway by a modification
of the above methods using microtiter wells that were coated
with mannan or human IgG, respectively. Diluted serum samples
were added to the wells at 4
 
 
 
C to avoid complement activation.
After incubation at 4
 
 
 
C and rinsing, human C4 was added and
incubated at 37
 
 
 
C. The wells were rinsed and deposited C4 frag- 
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ments were detected with biotinylated rabbit anti–human C4c
antibody followed by alkaline phosphatase–conjugated biotin–
avidin complex and 
 
p
 
-nitrophenyl phosphate substrate. OD 415
nm was measured.
 
S. aureus Infection.
 
All mice were between 6 and 12 wk old,
from generations F4–F11, and were maintained on a mixed back-
ground of 129Sv 
 
  
 
C57B/6J. Age- and gender-matched mice
were used in each experiment. The strains of 
 
S. aureus
 
 used were
Reynolds capsular serotype 5 (
 
S. aureus
 
 CP5; provided by J.C.
Lee, Brigham and Women’s Hospital, Boston, MA; 56, 57) and
bioluminescent 
 
S. aureus
 
 Xen 8.1 (biolumi-
 
S. aureus
 
; provided by
K.P. Francis, Xenogen Corp., Alameda, CA), which is a modifi-
cation of 
 
S. aureus
 
 8325–4 (58). The biolumi-
 
S. aureus
 
 was used
for studies of in vivo imaging, whereas the rest of the studies
were performed with the 
 
S. aureus
 
 CP5. 
 
S. aureus
 
 was grown
overnight in Columbia media with 2% NaCl, washed once, and
resuspended in saline. Mice were inoculated i.v. in the tail vein
with 5 
 
  
 
10
 
6
 
, 5 
 
  
 
10
 
7
 
, or 5 
 
  
 
10
 
8 
 
CFU/0.2 ml saline/mouse,
evaluated for complications of infection, and 5 
 
  
 
10
 
7 
 
CFU/
mouse was chosen as the optimal dose. Dose response for i.p. in-
oculation was performed with 4 
 
  
 
10
 
5
 
, 4 
 
  
 
10
 
6
 
, and 4 
 
  
 
10
 
7
 
CFU/0.5 ml saline/mouse, and 2 
 
  
 
10
 
6 
 
CFU/mouse was the op-
timal dose. Neutropenia was induced by i.p. injection of cyclo-
phosphamide (CY) at 150 and 100 mg/kg at 4 and 1 d before 
 
S.
aureus
 
 inoculation, respectively.
For reconstitution experiments, 75 
 
 
 
g rhMBL (provided by
NatImmune A/S) in 0.2 ml saline/mouse was injected i.p. 1 h
before the inoculation and then daily for 3 d after inoculation be-
cause a half-life of rhMBL via i.p. injection was 14–20 h (un-
published data). Serum levels of rhMBL measured at 1 d after
injection ranged between 5 and 11 
 
 
 
g/ml, which is in the phys-
iological range in mouse.
 
In Vivo Bioluminescence Imaging.
 
The low light imaging sys-
tem (Hamamatsu Photonics KK) has been previously described in
detail (59).
 
Bacterial Load in Blood and Organs.
 
Blood was collected from
the tail vein and immediately mixed with heparin. Organs were
harvested from killed mice, weighed, and homogenized in saline
(2 ml for liver and 1 ml for the other organs). Serial dilutions of
the blood and the organ homogenates were cultured on tryptic
soy agar plates supplemented with 5% sheep blood plates (TSA-
II) overnight at 37
 
 
 
C. CFUs were calculated as CFU/ml for
blood and CFU/g of wet weight for organs.
 
Bacterial Growth Assay in Plasma, Serum, and Whole Blood.
 
Plasma and serum were collected from hirudin-treated blood and
coagulated blood at room temperature for 2 h, respectively. 60 
 
 
 
l
serum, plasma, or hirudin-treated blood was mixed with 
 
S. aureus
 
CP5 (10
 
5 
 
CFU/ml) in a 100-
 
 
 
l reaction volume. After the mix-
tures were cultured at 37
 
 
 
C for 2 h, 10-
 
 
 
l samples were re-
moved, diluted, and plated on TSA-II plates. CFUs were deter-
mined after overnight culture.
 
Cytokine Assay.
 
TNF-
 
  
 
and IL-6 were measured by ELISA
kits (R&D Systems) according to the manufacturer’s instructions
as previously described (48).
 
Phagocytosis Assays.
 
Resident peritoneal macrophages were
obtained by peritoneal lavage. FITC-labeled 
 
S. aureus
 
 CP5
(FITC-
 
S. aureus
 
) was opsonized in 40% serum (vol/vol in HBSS)
at 37
 
 
 
C for 30 min, washed, and suspended in 100 
 
 
 
l HBSS to a
concentration of 2.5 
 
  
 
10
 
8 
 
cells/ml. 1.25 
 
  
 
10
 
5 
 
macrophages
were mixed with 1.25 
 
  
 
10
 
7 
 
opsonized FITC-
 
S. aureus
 
 in 100 
 
 
 
l
HBSS and incubated at 37
 
 
 
C for 30 min. The extracellular fluo-
rescence was quenched by the addition of 200 
 
 
 
l PBS containing
0.04% trypan blue and 1% formaldehyde, pH 5.5, and ingested
bacteria were scored by flow cytometry (60). Triplicate experi-
ments were repeated twice. For in vivo phagocytosis assay, 2 
 
 
 
10
 
7 
 
FITC-
 
S. aureus
 
 were inoculated i.p. and 10 min thereafter
peritoneal cells were collected individually by peritoneal lavage
and washed once before quenching. Flow cytometry assays were
performed on a FACSCalibur™ (BD Biosciences). Results were
analyzed using CELLQuest™ software.
Figure 1. Generation and characterization of MBL-null mice. (a)
MBL-C targeting construct. Genomic organization of MBL-C is shown
and compared with the targeting vector and homologous recombinant. (b)
RT-PCR analysis of transcript for MBL-A, MBL-C, and serum amyloid
protein (SAP) in liver. (c) Serum levels of MBL-A and MBL-C in WT,
MBL-C KO, and MBL-null mice.  , individual mice; bars, the mean
value for each group. (d) C4 cleaving activity of serum. The capacity of
serum to activate C4 via the MBL complement pathway (left) or classical
pathway (right) was assayed as described above.  , individual mice; bars,
the mean value for each group. (e) C4 cleaving activity. Comparison of
rhMBL with purified MBL-A and MBL-C.  , rhMBL;  , MBL-A;
 , MBL-C. 
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Statistical Analysis.
 
Data of abscess formation was assessed by
 
 
 
2
 
-test (JMP5 software; SAS Institute). Data of bacterial loads was
analyzed by ANOVA using Statview (SAS Institute).
 
Results
 
Generation and Characterization of MBL-null Mice.
 
MBL-
null mice were generated by crossing MBL-A KO and
MBL-C KO mice. MBL-C KO mice were created by in-
troducing neo
 
r 
 
gene into exon 5 (Fig. 1 a). MBL-A KO
mice were generated previously (48). Disruption of the
MBL genes was confirmed by the lack of mRNA for
MBLs in the liver, the principle site of MBL synthesis (49),
and undetectable MBLs in serum (Fig. 1, b and c). MBL-A
KO, MBL-C KO, and MBL-null mice were healthy, via-
ble, fertile, and appeared normal with no obvious develop-
mental defects (not depicted). Histological examination of
lung, liver, spleen, lymph node, kidney, brain, and intestine
derived from mice 6–10 wk old did not reveal any obvious
abnormality (unpublished data).
Next, we examined the MBL complement pathway in
both MBL-C KO and MBL-null mice. This third novel
pathway of complement activation requires that MBL en-
gages a ligand to trigger the activation of MASPs that
generate the C3 convertase, C4bC2b (22, 23). The MBL-
dependent deposition of C4b is therefore an accurate
measurement of this pathway. Previously we reported that
serum levels of MBL-C in MBL-A KO mice were similar
to levels in WT mice and that the MBL complement path-
way in these MBL-A KO mice was half that of WT mice
(48). These results suggested that both MBL-A and MBL-
C contributed to this pathway in mice. MBL-C KO mice
had slightly elevated serum levels of MBL-A compared
with WT mice (Fig. 1 c). This result is likely explained by
the fact that MBL-A is an acute phase reactant. However,
as was observed in MBL-A KO mice, the MBL comple-
ment pathway was reduced by 50% in MBL-C mice (Fig. 1
d). To investigate the relative complement-activating abil-
ity of MBL-A and MBL-C, we performed a dose response
using purified MBL-C and MBL-A (43) that were added
back to MBL-null mouse serum, and then measured MBL-
dependent C4 deposition. The specific activity of MBL-A
was approximately four times that of MBL-C (Fig. 1 e).
However, the serum levels of MBL-C were threefold those
of MBL-A in WT mice (Fig. 1 c). Taken together, these
results indicate that MBL-A and MBL-C have equivalent
total activity in serum. Importantly and relevant to later re-
constitution experiments, rhMBL was active in mouse se-
rum in vitro and its specific activity was equal to that of
mouse MBL-A and four times that of MBL-C (Fig. 1 e).
This suggests that in so far as complement activation is con-
cerned, MBL-A and MBL-C are redundant. As expected,
the MBL complement pathway was not functional in
MBL-null mice as neither MBL-A nor MBL-C is found in
the serum (Fig. 1 d, left). As shown in Fig. 1 d, the classical
pathway was unaffected in MBL-null mice.
 
MBL-null Mice Are Highly Susceptible to S. aureus Bactere-
mia.
 
Resistance against 
 
S. aureus
 
 is multifactorial. The
products of neutrophils and platelets, complement and pep-
tidoglycan recognition proteins like Toll-like receptor 2, are
key components in the initial armamentarium against this
pathogen (61, 62). Furthermore, it has recently been shown
in vitro that complement-dependent killing of S. aureus is
mediated via the MBL complement pathway rather than the
classical or the alternative complement pathways (25). To
evaluate the in vivo role of MBL against infection with S.
aureus, WT and MBL-null mice were inoculated i.v. with
5   107 CFU S. aureus/mouse and survival was monitored.
Figure 2. Increased mortality in MBL-null mice from S. aureus infection.
S. aureus was inoculated i.v. and survival was followed as described in
Materials and Methods. Numbers of mice used were 15 WT, 14 MBL-
null, and 9 MBL-null plus rhMBL. *, P   0.0001.
Figure 3. Increased bacterial loads in blood and organs
of MBL-null mice. Bacterial titers were assayed at 24 h
after i.v. inoculation of S. aureus as described in Materials
and Methods. Six mice were in each group. Open bars,
WT; closed bars, MBL-null. Bars indicate mean   SD. *,
P   0.05; **, P   0.01.Shi et al. 1383
At 48 h the mortality was 100% for MBL-null mice
compared with 55% survival for WT mice (Fig. 2). Fur-
thermore, pretreatment of MBL-null mice with rhMBL
partially rescued the phenotype in that the survival of
MBL-null mice was 45% by 48 h (Fig. 2). The phenotype
of MBL-A KO and MBL-C KO mice was similar to that of
WT mice (unpublished data). These results suggest that
these two forms of MBL play a redundant role in resistance
to S. aureus infection and that only when both proteins are
absent the susceptibility to S. aureus is revealed.
Next, we investigated whether the enhanced susceptibil-
ity of MBL-null mice to S. aureus infection was a result of
altered distribution and growth of the bacteria in the blood,
kidney, spleen, liver, and lung. One and a half logs more
CFU/ml was found in the blood of MBL-null mice com-
pared with WT mice at 24 h after inoculation (Fig. 3). It
was not possible to examine the later kinetics of bacteremia
in MBL-null mice as all had died by 48 h, but longer studies
in WT mice that survived the infection indicated that these
mice sterilize the blood several days after inoculation (not
depicted). There were statistically significant higher bacte-
rial loads in the kidney, spleen, and liver in MBL-null mice
compared with WT mice at 24 h after inoculation (Fig. 3).
To evaluate the relative contribution of direct comple-
ment-mediated lysis and MBL-dependent opsonophagocy-
tosis, we incubated S. aureus in plasma and serum of WT,
MBL-null, and C3-null mice. We found that none of the
plasma (Fig. 4 a) and sera (not depicted) restricted the
growth of bacteria at 10 min or 2 h after inoculation. In ad-
dition, there was no difference in the growth rate at all
three conditions (Fig. 4 a). By contrast, ex vivo whole
blood killing assay revealed that after 2 h of incubation the
growth of S. aureus was restricted in whole blood from WT
mice compared with 10 min of incubation, whereas S. au-
reus continued to grow in whole blood from MBL-null
mice (Fig. 4 b). These results indicate that phagocytes,
MBL, and complement are required for S. aureus killing.
Role of MBL in Cytokine Response to S. aureus Infection.
The levels of TNF-  and IL-6 in the blood of MBL-null
and WT mice were determined at 2 and 24 h after the i.v.
inoculation. Both TNF-  and IL-6 (P   0.0001) were re-
duced in the serum of MBL-null mice compared with WT
mice at 2 h (Fig. 5). In contrast, at 24 h there was a 15-fold
increase in TNF-  (P   0.05) and an eightfold increase in
IL-6 (P   0.0005) in the serum of MBL-null mice com-
pared with WT mice (Fig. 5). Preliminary in vitro studies
with bone marrow–derived macrophages from MBL-null
mice that were cultured with heat-killed S. aureus showed
enhancement of IL-6 secretion at 24 h. A similar trend was
also observed for TNF-  secretion (unpublished data).
MBL and Neutrophils Are Required to Combat i.p. Challenge
of S. aureus. The role of MBL in restricting tissue infection
as it developed in the peritoneal cavity was evaluated. We
adapted a modified rat infection model of S. aureus (57) to
mice by administering the bacteria i.p. to achieve a slower
seeding into the blood and tissues. In this way we could as-
sess the role of MBL in combating infection in inflamed
body cavities. Bacteremia and abscess formation were evalu-
ated at various time points up to 10 d after i.p. inoculation
of S. aureus ranging between 4   105 and 4   107 CFU/
mouse. Even the highest dose of bacterial inoculation did
not show difference in survival between WT, MBL-A KO,
and MBL-null mice. We chose a dose of 2   106 CFU/
mouse and compared abscess formation in WT, MBL-A
KO, and MBL-null mice. There was no abscess formation
in organs that we examined in any of the mice tested (Fig.
6). We did not test MBL-C KO mice as we assumed that
they would be similar to MBL-A KO mice based on equiv-
alence of MBL-A– and MBL-C–dependent complement
pathway activity in the serum (Fig. 1 e). Of note, MBL is
detectable in the peritoneal cavity of WT mice within hours
of an inflammatory challenge (unpublished data).
Figure 4. Restricted bacterial growth in blood of WT mice and enhanced
growth in blood but not in plasma of MBL-null mice. Open bars, at 10
min; closed bars, at 2 h. (a) Bacterial growth in plasma. Results are shown
as a percentage of bacterial growth in WT plasma at 10 min. Pooled
plasma was used and the assay was performed in triplicates as described in
Materials and Methods. Bars indicate mean   SD. (b) Results are shown
as a percentage of bacterial growth in WT blood at 10 min. Blood was
collected from four mice individually and the assay was performed in
triplicates as described in Materials and Methods. Bars indicate mean   SD.
*, P   0.05MBL Deficiency and Infection 1384
Clinical observations indicate that cancer patients with
chemotherapy-induced neutropenia who have MBL hap-
lotypes that specify low serum levels of MBL have an in-
creased incidence of infections compared with similar
populations of MBL-sufficient patients (38, 63, 64). We
decided to simulate the clinical situation of febrile neutro-
penia to test this observation under controlled experimental
conditions. MBL-null and WT mice were rendered neu-
tropenic by i.p. injection of CY. 4 d after injection of CY
all mice were neutropenic, at which time these mice were
inoculated with S. aureus. By 10 d after inoculation, 21 out
of 29 neutropenic MBL-null mice developed significant
numbers of visible abscesses in organs compared with 3 out
of 15 neutropenic WT mice (Table I, P   0.0003).
The most frequent target organ in MBL-null mice was
the liver (17 out of 29) followed by the kidney (12 out of
29) and the lung (9 out of 29), whereas the spleen seemed
relatively resistant to later infection (2 out of 29; Table I).
There was no statistically significant difference between
the neutropenic MBL-A KO, neutropenic MBL-C KO,
and neutropenic WT mice, indicating that MBL-A and
MBL-C are redundant under these circumstances.
Neutropenic MBL-null Mice Accumulate More Bacteria in
Blood and Organs Compared with Neutropenic WT Mice by
Day 4 of Infection. The kinetics of bacterial proliferation
after infection in the peritoneal cavity was assayed. In par-
ticular, we aimed to test the role of MBL in the compli-
cated interplay between the bacteria and host. For S. aureus
Figure 5. Cytokine production after S. aureus infection.
Levels of cytokine induction was less at 2 h but more at 24 h
in MBL-null mice compared with WT mice after S. aureus
i.v. inoculation. Six mice were used in each group. Bars
indicate mean   SE. *, P   0.05; **, P   0.001.
Table I. Abscess Formation in Organs
Numbers of mice with abscess formation per total mice in each group
Kidney Liver Lung Spleen Any combination
WT   CY 1/15 3/15 1/15 0/15 3/15
MBL-A KO   CY 1/7 2/7 0/7 0/7 2/7
MBL-C KO   CY 0/9 3/9 0/9 0/9 3/9
MBL-null   CY 12/29 (0.010)a 17/29 (0.012) 9/29 (0.049) 2/29 21/29 (0.0003)
WT 0/8 0/8 0/8 0/8 0/8
MBL-A KO 0/7 0/7 0/7 0/7 0/7
MBL-null 0/9 0/9 0/9 0/9 0/9
aNumbers in parentheses indicate p-values against WT   CY mice group.Shi et al. 1385
infection, this revolves around the ability of the host to
adapt and resist the broad array of bacterially derived patho-
genicity factors. To this end, neutropenic WT and neutro-
penic MBL-null mice were inoculated i.p. with biolumi-S.
aureus and the resulting infection was followed for 1 h and
then daily after inoculation in real time by in vivo biolumi-
nescence imaging. The accumulation of bacteria in the kid-
ney and in the paratracheal lymph nodes was evident by day
2 in neutropenic MBL-null mice compared with no accu-
mulation in neutropenic WT mice (Fig. 6 a). For more de-
finitive proof, bacterial titers in blood and organ were de-
termined to quantitate biolumi-S. aureus. There was no
significant difference in bacterial titers in the blood until day
3 after inoculation. However, by day 4 there were two log
differences between neutropenic WT mice with 105 CFU/
ml and neutropenic MBL-null mice with 2   107 CFU/ml
(P   0.037). By day 8 the neutropenic WT mice had steril-
ized their blood, whereas there was persistent bacteremia in
the neutropenic MBL-null mice despite a recovery of cir-
culating neutrophils (unpublished data).
There was a 10–100-fold higher number of S. aureus in
the spleens and lungs of neutropenic MBL-null mice com-
pared with neutropenic WT mice, respectively (Fig. 6 b).
These bacterial titers in organs were consistent with the ab-
scess formation data presented above.
The Phenotype Is Reversed by Treatment of Neutropenic
MBL-null Mice with rhMBL. We investigated the effect of
treating neutropenic MBL-null mice with rhMBL. Neu-
tropenic MBL-null mice that received rhMBL had no de-
tectable collections of biolumi-S. aureus in their organs
(Fig. 6 a). Bacterial culture of organs confirmed that
rhMBL-treated neutropenic MBL-null mice had 20–100
times less accumulation of bacteria in the spleens and lungs,
respectively, compared with untreated neutropenic MBL-
null mice (Fig. 6 b).
As expected, the MBL complement pathway was intact
in neutropenic WT mice but not in neutropenic MBL-null
mice before infection (Fig. 6 c, left). The MBL comple-
ment pathway was restored in vivo in neutropenic MBL-
null mice that received rhMBL (Fig. 6 c, right). These
findings indicate that the reconstitution of the MBL com-
plement pathway directly correlated with a decrease in bac-
terial accumulation in the tissues.
Decreased Bacterial Phagocytosis by Resident Peritoneal Macro-
phages in MBL-null Mice. In this study we observed that
neutropenic MBL-null mice are more susceptible to i.p. in-
fection than neutropenic WT mice. CY-treated WT and
MBL-null mice, in addition to being neutropenic, had an
80% decrease in circulating monocytes and resident perito-
neal macrophages, indicating that the effects of chemother-
apy did not affect neutrophils alone. We reasoned that de-
spite the reduction in the number, resident peritoneal
macrophages, together with MBL, play a key role in re-
stricting the early infection in the absence of neutrophils.
We detected MBL in the peritoneal cavity of WT mice
within hours of infection (unpublished data). Resident
peritoneal macrophages were harvested 10 min after inocu-
lation of FITC-S. aureus into the peritoneal cavity of WT
Figure 6. Increased S. aureus infection in MBL-null mice and rescued
MBL complement pathway by rhMBL in MBL-null mice. (a) In vivo
imaging of mice at 48 h after inoculation of the biolumi-S. aureus was
performed as described in Materials and Methods. Representative pictures
from WT, MBL-null, and MBL-null mice that were reconstituted with
rhMBL (MBL null plus rhMBL) are shown. (b) Increased level of bacteria
in organs from MBL-null mice. Organs were harvested at 96 h after
the infection with biolumi-S. Aureus and bacterial load was measured
as described in Materials and Methods. Bars indicate mean   SD. Numbers
of mice used: WT, 8; MBL-null, 7; MBL-null plus rhMBL, 7. (c) MBL
complement pathway activity before and after S. aureus CP5 infection.
Plasma was collected at 4 d before as a base line and 4 d after S. aureus
inoculation and analyzed for C4 deposition activity on mannan as de-
scribed in Materials and Methods. Numbers of mice used before infection:
WT, 12; MBL-null, 19. Numbers of mice used after infection: WT,
12; MBL-null, 10; MBL-null plus rhMBL, 9. Two experiments were
combined. Bars indicate mean   SD. *, P   0.002.MBL Deficiency and Infection 1386
and MBL-null mice, and phagocytosis as bacterial uptake
was analyzed by FACS®. There was a 40% reduction in
bacterial phagocytosis by resident peritoneal macrophages
from MBL-null mice compared with those from WT mice
(Fig. 7). In addition, the bacterial phagocytosis in vitro by
peritoneal macrophages from WT mice was 35% less when
FITC-S. aureus was opsonized with serum from MBL-null
mice compared with that from WT mice.
Discussion
In this study we demonstrate that mice that lack MBL-A
and MBL-C (Fig. 1 c) and thereby do not have a functional
MBL complement pathway (Fig. 1 d) are highly susceptible
to infection with S. aureus. All MBL-null mice died by 48 h
after i.v. inoculation of S. aureus (Fig. 2) and there was a
corresponding 10–100-fold increase in S. aureus accumula-
tion in blood, liver, spleen, kidney, and lung of MBL-null
mice compared with those of WT mice 24 h after inocula-
tion (Fig. 3). The persistent bacteremia led to overwhelm-
ing sepsis and the demise of the MBL-null mice. S. aureus
was killed in whole blood of WT mice, whereas the bacte-
ria grew in that of MBL-null mice (Fig. 4). In addition,
pretreatment of MBL-null mice with rhMBL reversed the
susceptibility phenotype. These results suggest that MBL
under the conditions of this mouse model has a nonredun-
dant role in restricting the spread of S. aureus from the
blood to the tissues.
MBL and MASPs circulate in the serum as complexes
(65). Once MBL recognizes a microbial surface, MASP-2
coops the classical complement pathway convertase, which
in turn leads to the deposition of the cleaved third comple-
ment component C3b (22, 23). The C3b serves as a ligand
for complement receptors that are expressed on phagocytes.
In addition to the enhancement of opsonophagocytosis, ac-
tivation of the MBL complement pathway may result in the
assembly of the membrane attack complex with the result-
ant fluid phase lysis of the target microorganism. MBL may
also directly opsonize targets for clearance by phagocytic
cells that express collectin receptors. A recent study evalu-
ated the relative importance of MBL-dependent clearance
mechanisms in vitro as it pertains to S. aureus (25). Impor-
tantly, that study revealed that the MBL complement path-
way, but not the alternative complement pathway, was re-
quired for antibody-independent C3 deposition on S.
aureus. In addition, it was observed that C3 opsonization of
S. aureus resulted in enhanced uptake of organisms by hu-
man neutrophils. Furthermore, MBL alone in the absence
of complement was also able to facilitate enhanced uptake
of bacteria by phagocytic cells. We attempted to address the
relative importance of these three mechanisms in defense
against S. aureus. Plasma and serum from WT, MBL-null,
and C3-null mice were not effective in restricting the
growth of S. aureus (Fig. 4), indicating that S. aureus is resis-
tant to direct attack via MBL, complement, or the combi-
nation of MBL and complement. However, phagocytosis of
S. aureus in whole blood was highly dependent of MBL
(Fig. 4). Taken together, our results indicate that MBL-ini-
tiated opsonophagocytosis by both neutrophils and macro-
phages is an important first line host defense against S. au-
reus. Our studies did not address the relative role of MBL
alone versus MBL-mediated complement activation in me-
diating opsonophagocytosis. We hope to address this point
in part by creating C3   MBL-null animals. Uptake of S.
aureus by phagocytes can also occur via macrophage scaven-
ger receptors in an opsonin-independent manner (66).
The net effect uptake by PMNs results in the triggering
of the oxidative burst and the release of peptides and pro-
teins like phospholipase A2 (67), cathelicidins (68), de-
fensins (69), and cathepsin G (70), all of which can directly
kill staphylococci. It would be interesting to compare
MBL-dependent release of these mediators with MBL-inde-
pendent release of these effectors as the next step in better
understanding of the MBL-dependent killing of S. aureus.
This study demonstrated that MBL not only acts as an
opsonin, but also stimulates a proinflammatory response.
We noted that there was a muted cytokine response as de-
fined by IL-6 and TNF-  levels in blood of MBL-null ani-
mals at 2 h after inoculation (Fig. 5). The failure to contain
the infection led to sepsis and death of all the MBL-null
mice by 48 h with high levels of IL-6 and TNF-  (Fig. 5)
commensurate with an exaggerated host response to bacte-
rial sepsis. These in vivo findings correlate with our in vitro
findings in that S. aureus preincubated with serum from
MBL-null mice was relatively ineffective in triggering cyto-
kine release via macrophages (unpublished data). Based on
past studies (71) we postulate that the release of appropriate
amounts of TNF-  stimulates neutrophils and monocytes to
possess enhanced killing activity against S. aureus, as this was
described in an in vitro study (72). We hypothesized that
the relative lack of TNF-  resulted in less than optimal
stimulation of neutrophils and together with the failure to
activate MBL complement pathway contributed to the en-
hanced susceptibility of MBL-null mice to infection.
We wished to evaluate the intertwining role of MBL and
neutrophils further, and reasoned that local anti-staphylo-
cocci defenses would combat a low multiplicity of infec-
tion in the first instance in this body compartment. Such
Figure 7. Decreased macrophage phagocytosis in MBL-null mice.
Phagocytosis was assayed in vivo (a) and in vitro (b) as described in
Materials and Methods. Phagocytosis is shown by mean fluorescence
intensity for the ingested FITC-S. aureus. Bars indicate mean   SE.
**, P   0.003; *, P   0.009.Shi et al. 1387
defense mechanisms would be supplemented during the
acute inflammatory response that would include both neu-
trophils and MBL. Our findings that MBL-null and WT
mice were equally resistant to sublethal challenge of S. au-
reus (Table I) demonstrate that MBL complement pathway
alone is redundant in first line host defense against staphy-
lococci in the peritoneal cavity. This is in contrast to infec-
tion in blood where MBL appears to have a nonredundant
role. The well-documented anti-staphylococcal action of
platelets, phagocytic cells, and their products appear suffi-
cient to compensate for the lack of MBL. However, the in-
creased abscess formation in neutropenic MBL-null mice
compared with neutropenic WT mice indicates that MBL,
neutrophils, and resident peritoneal macrophages together
provide an effective barrier to i.p. infection with S. aureus.
It appears that in the absence of neutrophils and MBL, the
pathogen obtains a growth advantage and spreads beyond
the initial infectious nidus in the peritoneal cavity to the
paratracheal lymph nodes (Fig. 6 a). In the neutropenic
MBL-null mice systemic bacterial infection ensues within
days after the infectious inoculum. Organs are seeded with
pathogenic bacteria and abscess formation is observed in 21
out of 29 neutropenic MBL mice versus 3 out of 15 neu-
tropenic WT mice (Table I). The restoration of MBL with
exogenous MBL was required to contain the infection both
locally and systemically and correlated with the restoration
of the MBL complement pathway in vivo (Fig. 6 c).
Therefore, MBL fulfills the requirements that might be ex-
pected of a molecule involved in innate immunity as it is
required to limit an early response to infection in the
blood. Additionally, MBL is important in containing the
spread of an i.p. infection, at least under the experimental
conditions described in this study. Other serum opsonins,
like LBP, act in concert with neutrophils and have a selec-
tive action against certain Gram-negative pathogens that
might be dependent on the route of infection (35). In this
regard, LBP-null mice are uniquely susceptible to i.p. but
not per oral or i.v. infection with Salmonella typhimurium
and  S. aureus (35). On the other hand, MBL binds a
broader range of bacteria, fungi, certain parasites, and vi-
ruses (7). The availability of MBL-null mice will be useful
in adjudicating the relative role of MBL in maintaining the
balance between the host and other bacterial, viral, and
protozoan pathogens.
The establishment of an infection reflects a balance be-
tween the virulence of the organism and susceptibility of
the individual. We did not examine a wide range of S. au-
reus clinical isolates in this study but it is clear that S. aureus
uses cell-associated products, secreted exotoxins, and regu-
latory loci to enhance and modify its pathogenicity. Treat-
ment of S. aureus infections has become difficult given the
emergence of widespread antibiotic resistance (52). Clinical
isolates resistant to methicillin now appear to be resistant to
multiple antibiotics with the recent appearance of full resis-
tance to vancomycin (50). This raises the possibility that
rhMBL may have an adjuvant role clinically together with
antibiotics against antibiotic-resistant staphylococci. The
idea that MBL might be an infection susceptibility gene is
supported by the earliest studies by Super et al. (14) and
Sumiya et al. (15). Since that time, numerous studies have
indicated an association of low MBL levels with recurrent
infections in both adults and children. In one study a higher
proportion of patients with invasive pneumococcal disease
were homozygous for MBL variant genes compared with
age- and race-matched controls (73). The interdependence
of MBL and neutrophils in combating infection also has a
clinical corollary. Neth et al. (63) found that children with
febrile neutropenia after chemotherapy who had low secre-
tor MBL haplotypes stayed in the hospital an average of 2 d
longer than those who were MBL sufficient. Two other
studies in adult cancer patients demonstrated an association
between low MBL levels and clinically significant events in
the setting of febrile neutropenia, whereas one study failed
to demonstrate this association (38). The increased suscep-
tibility to infection of patients with cystic fibrosis, chronic
granulomatous disease, complement deficiency, common
variable immunodeficiency, and antibody subclass defi-
ciency who have low MBL secretor haplotypes provides
further credence to the idea that MBL synergies with other
modalities of host defense (6). Taken together, these exam-
ples illustrate that MBL acts in concert with other modali-
ties of the innate immune system to alter the balance be-
tween the host and the pathogen. Our study adds credence
to this paradigm but also indicates that if the infection is
blood born, MBL has a nonredundant role, at least in the
context of S. aureus bacteremia. However, for tissue, infec-
tious susceptibility required not only MBL deficiency, but
also a second hit, which in this instance was neutropenia.
It would be interesting to assess the association of MBL
variants and complications of S. aureus bacteremia in large
cohort human studies. Given the results of this study one
might predict that MBL levels might be an additional clini-
cal identifier that is a biological marker of host resistance.
Finally, our study provides direct in vivo evidence that
MBL does indeed function as an “ante-antibody” in first
line host defense in that the MBL together with MBL
complement pathway is an important host factor that pro-
tects against the bacterial infection.
The authors thank members of the Laboratory of Developmental
Immunology at the Massachusetts General Hospital for helpful dis-
cussion and critical reading of this manuscript. The authors also
thank Dr. Jean C. Lee, Channing Laboratory, the Brigham and
Women’s Hospital, Harvard Medical School and Dr. Kevin P.
Francis, Xenogen Corp., for providing S. aureus CP5 and Biolumi-
nescent S. aureus Xen 8.1, respectively. The authors also thank Nat-
Immune A/S and Dr. K Moore, Lipid Metabolism Unit at the Mas-
sachusetts General Hospital for providing rhMBL and KO3 vector,
respectively. The authors acknowledge the Transgenic Knockout
Mouse Core facility for generation of the MBL-C–null mice at the
Massachusetts General Hospital, in particular, Dr. En Li, Mrs. Lian
Wu, and Mong Lei. We also acknowledge the Department of Mo-
lecular Biology for use of the FACSCalibur™ System.
This research is supported by grant NIH RO1AI42788. Conflict
of interest: R.A.B. Ezekowitz, S. Thiel, and J.C. Jensenius have a
financial interest in NatImmune, which is the company that sup-
plied the rhMBL.MBL Deficiency and Infection 1388
Submitted: 19 December 2003
Accepted: 24 March 2004
References
1. Janeway, C.A. 1989. Approaching the asymptote: evolution
and revolution in immunology. Cold Spring Harb. Symp.
Quant. Biol. 54:1–13.
2. Ezekowitz, R.A.B., and J. Hoffmann. 1998. Innate immu-
nity: the blossoming of innate immunity (editorial overview).
Curr. Opin. Immunol. 10:9–11.
3. Hoffmann, J.A., F.C. Kafatos, C.A. Janeway, and R.A.
Ezekowitz. 1999. Phylogenetic perspectives in innate immu-
nity. Science. 284:1313–1318.
4. Tobias, P.S., and R.J. Ulevitch. 1994. Lipopolysaccharide-
binding protein and CD14 in the lipopolysaccharide-depen-
dent activation of cells. Chest. 105:48s–50s.
5. Lu, J., C. Teh, U. Kishore, and K.B. Reid. 2002. Collectins
and ficolins: sugar pattern recognition molecules of the mam-
malian innate immune system. Biochim. Biophys. Acta. 1572:
387–400.
6. Holmskov, U., S. Thiel, and J.C. Jensenius. 2003. Collec-
tions and ficolins: humoral lectins of the innate immune de-
fense. Annu. Rev. Immunol. 21:547–578.
7. Fraser, I.P., H. Koziel, and R.A. Ezekowitz. 1998. The se-
rum mannose-binding protein and the macrophage mannose
receptor are pattern recognition molecules that link innate
and adaptive immunity. Semin. Immunol. 10:363–372.
8. Holmskov, U., R. Malhotra, R.B. Sim, and J.C. Jensenius.
1994. Collectins: collagenous C-type lectins of the innate
immune defense system. Immunol. Today. 15:67–74.
9. Turner, M.W., and R.M. Hamvas. 2000. Mannose-binding
lectin: structure, function, genetics and disease associations.
Rev. Immunogenet. 2:305–322.
10. Epstein, J., Q. Eichbaum, S. Sheriff, and R.A.B. Ezekowitz.
1996. The collectins in innate immunity. Curr. Opin. Immu-
nol. 8:29–35.
11. Ikeda, K., T. Sannoh, N. Kawasaki, T. Kawasaki, and I. Ya-
mashina. 1987. Serum lectin with known structure activates
complement through the classical pathway. J. Biol. Chem.
262:7451–7454.
12. Drickamer, K., M.S. Dordal, and L. Reynolds. 1986. Man-
nose-binding proteins isolated from rat liver contain car-
bohydrate-recognition domains linked to collagenous tails.
Complete primary structures and homology with pulmonary
surfactant apoprotein. J. Biol. Chem. 261:6878–6887.
13. Kuhlman, M., K. Joiner, and R.A. Ezekowitz. 1989. The
human mannose-binding protein functions as an opsonin. J.
Exp. Med. 169:1733–1745.
14. Super, M., S. Thiel, J. Lu, R.J. Levinsky, and M.W. Turner.
1989. Association of low levels of mannan-binding protein
with a common defect of opsonisation. Lancet. 2:1236–1239.
15. Sumiya, M., M. Super, P. Tabona, R.J. Levinsky, T. Arai,
M.W. Turner, J.A. Summerfield, S. Thiel, and J. Lu. 1991.
Molecular basis of opsonic defect in immunodeficient chil-
dren. Lancet. 337:1569–1570.
16. Madsen, H.O., M.L. Satz, B. Hogh, A. Svejgaard, and P.
Garred. 1998. Different molecular events result in low pro-
tein levels of mannan-binding lectin in populations from
southeast Africa and South America. J. Immunol. 161:3169–
3175.
17. Super, M., S.D. Gillies, S. Foley, K. Sastry, J.E. Schweinle,
V.J. Silverman, and R.A. Ezekowitz. 1992. Distinct and
overlapping functions of allelic forms of human mannose
binding protein. Nat. Genet. 2:50–55.
18. Madsen, H.O., P. Garred, S. Thiel, J.A. Kurtzhals, L.U.
Lamm, L.P. Ryder, and A. Svejgaard. 1995. Interplay be-
tween promoter and structural gene variants control basal se-
rum level of mannan-binding protein. J. Immunol. 155:3013–
3020.
19. Ogden, C.A., A. deCathelineau, P.R. Hoffmann, D. Brat-
ton, B. Ghebrehiwet, V.A. Fadok, and P.M. Henson. 2001.
C1q and mannose binding lectin engagement of cell surface
calreticulin and cd91 initiates macropinocytosis and uptake of
apoptotic cells. J. Exp. Med. 194:781–796.
20. Sheriff, S., C.Y. Chang, and R.A. Ezekowitz. 1994. Human
mannose-binding protein carbohydrate recognition domain
trimerizes through a triple alpha-helical coiled-coil. Nat.
Struct. Biol. 1:789–794. (erratum published 3:103).
21. Weis, W.I., M.E. Taylor, and K. Drickamer. 1998. The
C-type lectin superfamily in the immune system. Immunol.
Rev. 163:19–34.
22. Matsushita, M., and T. Fujita. 1992. Activation of the classi-
cal complement pathway by mannose-binding protein in as-
sociation with a novel C1s-like serine protease. J. Exp. Med.
176:1497–1502.
23. Thiel, S., T. Vorup-Jensen, C.M. Stover, W. Schwaeble,
S.B. Laursen, K. Poulsen, A.C. Willis, P. Eggleton, S.
Hansen, U. Holmskov, et al. 1997. A second serine protease
associated with mannan-binding lectin that activates comple-
ment. Nature. 386:506–510.
24. Valdimarsson, H., M. Steffansson, T. Vikingsdottir, G.J. Ara-
son, C. Koch, S. Thiel, and J.C. Jensenius. 1998. Reconstitu-
tion of opsonizing activity by infusion of mannan-binding
lectin (MBL) to MBL-deficient humans. Scand. J. Immunol.
48:116–123.
25. Neth, O., D.L. Jack, M. Johnson, N.J. Klein, and M.W.
Turner. 2002. Enhancement of complement activation and
opsonophagocytosis by complexes of mannose-binding lectin
with mannose-binding lectin-associated serine protease after
binding to Staphylococcus aureus. J. Immunol. 169:4430–4436.
26. Super, M., R.J. Levinsky, M.W. Turner, S. Thiel, and J. Lu.
1990. Association of low levels of mannan-binding protein
with a common defect of opsonisation. Clin. Exp. Immunol.
79:144–150.
27. Matsukawa, A., C.M. Hogaboam, N.W. Lukacs, P.M. Lin-
coln, H.L. Evanoff, and S.L. Kunkel. 2000. Pivotal role of
the CC chemokine, macrophage-derived chemokine, in the
innate immune response. J. Immunol. 164:5362–5368.
28. Chinnaiyan, A.M., M. Huber-Lang, C. Kumar-Sinha, T.R.
Barrette, S. Shankar-Sinha, V.J. Sarma, V.A. Padgaonkar,
and P.A. Ward. 2001. Molecular signatures of sepsis: multi-
organ gene expression profiles of systemic inflammation. Am.
J. Pathol. 159:1199–1209.
29. Holmskov, U.L. 2000. Collectins and collectin receptors in
innate immunity. APMIS Suppl. 100:1–59.
30. Wright, J.R. 1997. Immunomodulatory functions of surfac-
tant. Physiol. Rev. 77:931–962.
31. Wright, S.D., R.A. Ramons, P.S. Tobias, R.J. Ulevitch, and
J.C. Mathison. 1990. CD14 serves as the cellular receptor
for complexes of lipopolysaccharide with lipopolysaccharide
binding protein. Science. 249:1431–1433.
32. Wright, A.E., and S.R. Douglas. 1904. Opsonins. Proc R.
Soc. Ser. 73:128–142.
33. Silverstein, A.M. 2003. Cellular versus humoral immunol-
ogy: a century-long dispute. Nat. Immunol. 4:425–428.Shi et al. 1389
34. Yang, K.K., B.G. Dorner, U. Merkel, B. Ryffel, C. Schutt,
D. Golenbock, M.W. Freeman, R.S. Jack, J. Fierer, M.A.
Swancutt, et al. 2002. Neutrophil influx in response to a
peritoneal infection with Salmonella is delayed in lipopolysac-
charide-binding protein or CD14-deficient mice. J. Immunol.
169:4475–4480.
35. Fierer, J., M.A. Swancutt, D. Heumann, and D. Golenbock.
2002. The role of lipopolysaccharide binding protein in resis-
tance to Salmonella infections in mice. J. Immunol. 168:6396–
6403.
36. Garred, P., H.O. Madsen, J.A. Kurtzhals, L.U. Lamm, S.
Thiel, A.S. Hey, and A. Svejgaard. 1992. Diallelic polymor-
phism may explain variations of the blood concentration of
mannan-binding protein in Eskimos, but not in black Afri-
cans. Eur. J. Immunogenet. 19:403–412.
37. Summerfield, J.A., M. Sumiya, M. Levin, and M.W. Turner.
1997. Mannose-binding protein gene mutations are associ-
ated with childhood infection in a consecutive hospital series.
BMJ. 314:1229–1232.
38. Peterslund, N.A., C. Koch, J.C. Jensenius, and S. Thiel.
2001. Association between deficiency of mannose-binding
lectin and severe infections after chemotherapy. Lancet. 358:
637–638.
39. Turner, M.W. 1998. Mannose-binding lectin (MBL) in
health and disease. Immunobiology. 199:327–339.
40. Ezekowitz, R.A.B. 1991. Ante-antibody immunity. Curr.
Biol. 1:60–62.
41. Mogues, T., T. Ota, A.I. Tauber, and K.N. Sastry. 1996.
Characterization of two mannose-binding protein cDNAs
from rhesus monkey (Macaca mulatta): structure and evolu-
tionary implications. Glycobiology. 6:543–550.
42. Laursen, S.B., T.S. Dalgaard, S. Thiel, B.L. Lim, T.V. Jen-
sen, H.R. Juul-Madsen, A. Takahashi, T. Hamana, M.
Kawakami, and J.C. Jensenius. 1998. Cloning and sequenc-
ing of a cDNA encoding chicken mannan-binding lectin
(MBL) and comparison with mammalian analogues. Immunol-
ogy. 93:421–430.
43. Hansen, S., S. Thiel, A. Willis, U. Holmskov, and J.C. Jense-
nius. 2000. Purification and characterization of two mannan-
binding lectins from mouse serum. J. Immunol. 164:2610–
2618.
44. Lee, R.T., Y. Ichikawa, M. Fay, K. Drickamer, M.C. Shao,
and Y.C. Lee. 1991. Ligand-binding characteristics of rat se-
rum-type mannose-binding protein (MBP-A). Homology of
binding site architecture with mammalian and chicken he-
patic lectins. J. Biol. Chem. 266:4810–4815.
45. Ng, K.K., K. Drickamer, and W.I. Weis. 1996. Structural
analysis of monosaccharide recognition by rat liver mannose-
binding protein. J. Biol. Chem. 271:663–674.
46. Liu, H., L. Jensen, S. Hansen, S.V. Petersen, K. Takahashi,
A.B. Ezekowitz, F.D. Hansen, J.C. Jensenius, and S. Thiel.
2001. Characterization and quantification of mouse mannan-
binding lectins (MBL-A and MBL-C) and study of acute
phase responses. Scand. J. Immunol. 53:489–497.
47. Lee, S.J., G. Gonzalez-Aseguinolaza, and M.C. Nussenzweig.
2002. Disseminated candidiasis and hepatic malarial infection
in mannose-binding-lectin-A-deficient mice. Mol. Cell. Biol.
22:8199–8203.
48. Takahashi, K., J. Gordon, H. Liu, K. Sastry, J. Epstein, M.
Motwani, I. Laursen, S. Thiel, J. Jensenius, M. Carroll, et al.
2002. Lack of mannose-binding lectin-A enhances survival in
a mouse model of acute septic peritonitis. Microbes Infect.
4:773–784.
49. Uemura, K., M. Saka, T. Nakagawa, N. Kawasaki, S. Thiel,
J.C. Jensenius, and T. Kawasaki. 2002. L-MBP is expressed
in epithelial cells of mouse small intestine. J. Immunol. 169:
6945–6950.
50. Diekema, D.J., M.A. Pfaller, R.N. Jones, F.J. Schmitz, J.
Smayevsky, J. Bell, and M. Beach. 2002. Age-related trends
in pathogen frequency and antimicrobial susceptibility of
bloodstream isolates in North America: SENTRY Antimi-
crobial Surveillance Program, 1997-2000. Int. J. Antimicrob.
Agents. 20:412–418.
51. Chang, F.Y., J.E. Peacock, Jr., D.M. Musher, P. Triplett,
B.B. MacDonald, J.M. Mylotte, A. O’Donnell, M.M. Wage-
ner, and V.L. Yu. 2003. Staphylococcus aureus bacteremia: re-
currence and the impact of antibiotic treatment in a prospec-
tive multicenter study. Medicine (Baltimore). 82:333–339.
52. Melzer, M., S.J. Eykyn, W.R. Gransden, and S. Chinn.
2003. Is methicillin-resistant Staphylococcus aureus more viru-
lent than methicillin-susceptible S. aureus? A comparative co-
hort study of British patients with nosocomial infection and
bacteremia. Clin. Infect. Dis. 37:1453–1460.
53. Fowler, V.G., Jr., M.K. Olsen, G.R. Corey, C.W. Woods,
C.H. Cabell, L.B. Reller, A.C. Cheng, T. Dudley, and E.Z.
Oddone. 2003. Clinical identifiers of complicated Staphylococ-
cus aureus bacteremia. Arch. Intern. Med. 163:2066–2072.
54. Sastry, R., J.S. Wang, D.C. Brown, R.A. Ezekowitz, A.I.
Tauber, and K.N. Sastry. 1995. Characterization of murine
mannose-binding protein genes Mbl1 and Mbl2 reveals
features common to other collectin genes. Mamm. Genome.
6:103–110.
55. Petersen, S.V., S. Thiel, L. Jensen, R. Steffensen, and J.C.
Jensenius. 2001. An assay for the mannan-binding lectin
pathway of complement activation. J. Immunol. Methods. 257:
107–116.
56. Lee, J.C., M.J. Betley, C.A. Hopkins, N.E. Perez, and G.B.
Pier. 1987. Virulence studies, in mice, of transposon-induced
mutants of Staphylococcus aureus differing in capsule size. J. In-
fect. Dis. 156:741–750.
57. Lee, J.C., J.S. Park, S.E. Shepherd, V. Carey, and A. Fattom.
1997. Protective efficacy of antibodies to the Staphylococcus
aureus type 5 capsular polysaccharide in a modified model of
endocarditis in rats. Infect. Immun. 65:4146–4151.
58. Francis, K.P., D. Joh, C. Bellinger-Kawahara, M.J. Hawkin-
son, T.F. Purchio, and P.R. Contag. 2000. Monitoring bio-
luminescent Staphylococcus aureus infections in living mice
using a novel luxABCDE construct. Infect. Immun. 68:3594–
3600.
59. Hamblin, M.R., D.A. O’Donnell, N. Murthy, C.H. Contag,
and T. Hasan. 2002. Rapid control of wound infections by
targeted photodynamic therapy monitored by in vivo biolu-
minescence imaging. Photochem. Photobiol. 75:51–57.
60. Ramet, M., P. Manfruelli, A. Pearson, B. Mathey-Prevot,
and R.A. Ezekowitz. 2002. Functional genomic analysis of
phagocytosis and identification of a Drosophila receptor for E.
coli. Nature. 416:644–648.
61. Cunnion, K.M., H.M. Zhang, and M.M. Frank. 2003.
Availability of complement bound to Staphylococcus aureus to
interact with membrane complement receptors influences ef-
ficiency of phagocytosis. Infect. Immun. 71:656–662.
62. Molne, L., M. Verdrengh, and A. Tarkowski. 2000. Role
of neutrophil leukocytes in cutaneous infection caused by
Staphylococcus aureus. Infect. Immun. 68:6162–6167.
63. Neth, O., I. Hann, M.W. Turner, and N.J. Klein. 2001. De-
ficiency of mannose-binding lectin and burden of infectionMBL Deficiency and Infection 1390
in children with malignancy: a prospective study. Lancet. 358:
614–618.
64. Mullighan, C.G., S. Heatley, K. Doherty, F. Szabo, A. Grigg,
T.P. Hughes, A.P. Schwarer, J. Szer, B.D. Tait, L. Bik To, et
al. 2002. Mannose-binding lectin gene polymorphisms are as-
sociated with major infection following allogeneic hemopoi-
etic stem cell transplantation. Blood. 99:3524–3529.
65. Dahl, M.R., S. Thiel, M. Matsushita, T. Fujita, A.C. Willis,
T. Christensen, T. Vorup-Jensen, and J.C. Jensenius. 2001.
MASP-3 and its association with distinct complexes of the
mannan-binding lectin complement activation pathway. Im-
munity. 15:127–135.
66. Thomas, C.A., Y. Li, T. Kodama, H. Suzuki, S.C. Silver-
stein, and J. El Khoury. 2000. Protection from lethal Gram-
positive infection by macrophage scavenger receptor–depen-
dent phagocytosis. J. Exp. Med. 191:147–156.
67. Laine, V.J., D.S. Grass, and T.J. Nevalainen. 1999. Protec-
tion by group II phospholipase A2 against Staphylococcus au-
reus. J. Immunol. 162:7402–7408.
68. Midorikawa, K., K. Ouhara, H. Komatsuzawa, T. Kawai, S.
Yamada, T. Fujiwara, K. Yamazaki, K. Sayama, M.A. Taub-
man, H. Kurihara, et al. 2003. Staphylococcus aureus suscepti-
bility to innate antimicrobial peptides, beta-defensins and
CAP18, expressed by human keratinocytes. Infect. Immun. 71:
3730–3739.
69. Nakajima, Y., J. Ishibashi, F. Yukuhiro, A. Asaoka, D. Tay-
lor, and M. Yamakawa. 2003. Antibacterial activity and
mechanism of action of tick defensin against Gram-positive
bacteria. Biochim. Biophys. Acta. 1624:125–130.
70. Katzif, S., D. Danavall, S. Bowers, J.T. Balthazar, and W.M.
Shafer. 2003. The major cold shock gene, cspA, is involved
in the susceptibility of Staphylococcus aureus to an antimicrobial
peptide of human cathepsin G. Infect. Immun. 71:4304–4312.
71. Ferrante, A., A.J. Martin, E.J. Bates, D.H. Goh, D.P. Har-
vey, D. Parsons, D.A. Rathjen, G. Russ, and J.M. Dayer.
1993. Killing of Staphylococcus aureus by tumor necrosis fac-
tor-alpha-activated neutrophils. The role of serum opsonins,
integrin receptors, respiratory burst, and degranulation. J. Im-
munol. 151:4821–4828.
72. Bates, E.J., A. Ferrante, and L.J. Beard. 1991. Characteriza-
tion of the major neutrophil-stimulating activity present in
culture medium conditioned by Staphylococcus aureus-stimu-
lated mononuclear leukocytes. Immunology. 72:448–450.
73. Roy, S., K. Knox, S. Segal, D. Griffiths, C.E. Moore, K.I.
Welsh, A. Smarason, N.P. Day, W.L. McPheat, D.W. Crook,
et al. 2002. MBL genotype and risk of invasive pneumococcal
disease: a case-control study. Lancet. 359:1569–1573.